(MedPage Today) — HOUSTON — Patients with advanced or refractory cutaneous T-cell lymphoma (CTCL) achieved near-100% disease control with single-agent immunotherapy or an immuno-oncology (IO) combination, a small randomized trial showed.
Eight…
Source link : https://www.medpagetoday.com/meetingcoverage/soho/117343
Author :
Publish date : 2025-09-06 20:00:00
Copyright for syndicated content belongs to the linked Source.
